-
Je něco špatně v tomto záznamu ?
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom
T. Spelman, WL. Herring, C. Acosta, R. Hyde, VG. Jokubaitis, E. Pucci, A. Lugaresi, G. Laureys, EK. Havrdova, D. Horakova, G. Izquierdo, S. Eichau, S. Ozakbas, R. Alroughani, T. Kalincik, P. Duquette, M. Girard, T. Petersen, F. Patti, T. Csepany,...
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
- MeSH
- analýza nákladové efektivity MeSH
- analýza nákladů a výnosů MeSH
- fingolimod hydrochlorid terapeutické užití MeSH
- imunosupresiva terapeutické užití MeSH
- lidé MeSH
- natalizumab terapeutické užití MeSH
- relabující-remitující roztroušená skleróza * farmakoterapie MeSH
- roztroušená skleróza * farmakoterapie MeSH
- státní lékařství MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Spojené království MeSH
AIM: To evaluate the real-world comparative effectiveness and the cost-effectiveness, from a UK National Health Service perspective, of natalizumab versus fingolimod in patients with rapidly evolving severe relapsing-remitting multiple sclerosis (RES-RRMS). METHODS: Real-world data from the MSBase Registry were obtained for patients with RES-RRMS who were previously either naive to disease-modifying therapies or had been treated with interferon-based therapies, glatiramer acetate, dimethyl fumarate, or teriflunomide (collectively known as BRACETD). Matched cohorts were selected by 3-way multinomial propensity score matching, and the annualized relapse rate (ARR) and 6-month-confirmed disability worsening (CDW6M) and improvement (CDI6M) were compared between treatment groups. Comparative effectiveness results were used in a cost-effectiveness model comparing natalizumab and fingolimod, using an established Markov structure over a lifetime horizon with health states based on the Expanded Disability Status Scale. Additional model data sources included the UK MS Survey 2015, published literature, and publicly available sources. RESULTS: In the comparative effectiveness analysis, we found a significantly lower ARR for patients starting natalizumab compared with fingolimod (rate ratio [RR] = 0.65; 95% confidence interval [CI], 0.57-0.73) or BRACETD (RR = 0.46; 95% CI, 0.42-0.53). Similarly, CDI6M was higher for patients starting natalizumab compared with fingolimod (hazard ratio [HR] = 1.25; 95% CI, 1.01-1.55) and BRACETD (HR = 1.46; 95% CI, 1.16-1.85). In patients starting fingolimod, we found a lower ARR (RR = 0.72; 95% CI, 0.65-0.80) compared with starting BRACETD, but no difference in CDI6M (HR = 1.17; 95% CI, 0.91-1.50). Differences in CDW6M were not found between the treatment groups. In the base-case cost-effectiveness analysis, natalizumab dominated fingolimod (0.302 higher quality-adjusted life-years [QALYs] and £17,141 lower predicted lifetime costs). Similar cost-effectiveness results were observed across sensitivity analyses. CONCLUSIONS: This MSBase Registry analysis suggests that natalizumab improves clinical outcomes when compared with fingolimod, which translates to higher QALYs and lower costs in UK patients with RES-RRMS.
Aarhus University Hospital Arhus C Denmark
Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino Avellino Italy
Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases Istanbul Turkey
Biocruces Bizkaia Health Research Institute Spain
CHUM and Universite de Montreal Montreal Canada
Cliniques Universitaires Saint Luc Brussels Belgium
CORe Department of Medicine University of Melbourne Melbourne Australia
CSSS Saint Jérôme Saint Jerome Canada
Department of Clinical Neuroscience Karolinska Institute Stockholm Sweden
Department of General Medicine Parma University Hospital Parma Italy
Department of Medical and Surgical Sciences and Advanced Technologies GF Ingrassia Catania Italy
Department of Medicine and Surgery University of Cordoba Cordoba Spain
Department of Medicine and Surgery University of Parma Parma Italy
Department of Neurobiology Care Sciences and Society Karolinska Institute Stockholm Sweden
Department of Neurology and Stroke BAZ County Hospital Miskolc Hungary
Department of Neurology ASL3 Genovese Genova Italy
Department of Neurology Box Hill Hospital Melbourne Australia
Department of Neurology Centro Hospitalar Universitario de Sao Joao Porto Portugal
Department of Neurology Faculty of Medicine University of Debrecen Debrecen Hungary
Department of Neurology Hospital Clinico San Carlos Madrid Spain
Department of Neurology Hospital Universitario Virgen Macarena Seville Spain
Department of Neurology McGill University Montreal Canada
Department of Neurology Monash Health Clayton Australia
Department of Neurology Semmelweis University Budapest Budapest Hungary
Department of Neurology The Alfred Hospital Melbourne Australia
Department of Neurology University Hospital Ghent Ghent Belgium
Department of Neurology University of Szeged Szeged Hungary
Department of Neuroscience Azienda Ospedaliera Universitaria Modena Italy
Department of Neuroscience Central Clinical School Monash University Melbourne Australia
Department of Neuroscience Hospital Germans Trias i Pujol Badalona Spain
Department of Neuroscience Imaging and Clinical Sciences University G d'Annunzio Chieti Italy
Department of Neurosciences Box Hill Hospital Melbourne Australia
Department of Rehabilitation ML Novarese Hospital Moncrivello
Dipartamento di Scienze Biomediche e Neuromotorie Università di Bologna Bologna Italy
Division of Neurology Department of Medicine Amiri Hospital Sharq Kuwait
Faculty of Health Sciences University Fernando Pessoa Porto Portugal
Faculty of Medicine of Tunis University of Tunis El Manar Tunis Tunisia
Flinders University Adelaide Australia
Groene Hart Ziekenhuis Gouda Netherlands
Hacettepe University Ankara Turkey
Health Economics RTI Health Solutions NC USA
Hospital Universitario Donostia and IIS Biodonostia San Sebastián Spain
Immune Tolerance Laboratory Ingham Institute and Department of Medicine UNSW Sydney Australia
IRCCS Istituto delle Scienze Neurologiche di Bologna Bologna Italy
IRCCS Mondino Foundation Pavia Italy
Isfahan University of Medical Sciences Isfahan Iran
Izmir University of Economics Medical Point Hospital Izmir Turkey
Jahn Ferenc Teaching Hospital Budapest Hungary
Maimonides Biomedical Research Institute of Cordoba
Medical Biogen Baar Switzerland
Medical Faculty 19 Mayis University Samsun Turkey
Monash University Clayton Australia
Monash University Melbourne Australia
MS Centre Neurology Unit SS Annunziata University Hospital University G d'Annunzio Chieti Italy
MS Centre Royal Melbourne Hospital Melbourne Australia
MSBase Foundation Melbourne VIC Australia
Nemocnice Jihlava Jihlava Czech Republic
Neuroimmunology Centre Department of Neurology Royal Melbourne Hospital Melbourne Australia
Neurology Unit AST Fermo Fermo Italy
Neurology unit AST Macerata Macerata Italy
Ospedali Riuniti di Salerno Salerno Italy
Royal Brisbane and Women's Hospital Herston Australia
Royal Victoria Hospital Belfast United Kingdom
School for Mental Health and Neuroscience Maastricht University Maastricht The Netherlands
School of Medicine University of Bari Bari Italy
South Eastern HSC Trust Belfast United Kingdom
Universidade Metropolitana de Santos Santos Brazil
Université Catholique de Louvain Belgium
University of Queensland Brisbane Australia
UOS Sclerosi Multipla AOU Policlinico G Rodloico San Marco University of Catania Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24000101
- 003
- CZ-PrNML
- 005
- 20240213092949.0
- 007
- ta
- 008
- 240109s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/13696998.2023.2293379 $2 doi
- 035 __
- $a (PubMed)38085684
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Spelman, T $u MSBase Foundation, Melbourne, VIC, Australia $u Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden $1 https://orcid.org/0000000192043216
- 245 10
- $a Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom / $c T. Spelman, WL. Herring, C. Acosta, R. Hyde, VG. Jokubaitis, E. Pucci, A. Lugaresi, G. Laureys, EK. Havrdova, D. Horakova, G. Izquierdo, S. Eichau, S. Ozakbas, R. Alroughani, T. Kalincik, P. Duquette, M. Girard, T. Petersen, F. Patti, T. Csepany, F. Granella, F. Grand'Maison, D. Ferraro, R. Karabudak, M. Jose Sa, M. Trojano, V. van Pesch, B. Van Wijmeersch, E. Cartechini, P. McCombe, O. Gerlach, D. Spitaleri, C. Rozsa, S. Hodgkinson, R. Bergamaschi, R. Gouider, A. Soysal, . Castillo-Triviño, J. Prevost, J. Garber, K. de Gans, R. Ampapa, M. Simo, JL. Sanchez-Menoyo, G. Iuliano, A. Sas, A. van der Walt, N. John, O. Gray, S. Hughes, G. De Luca, M. Onofrj, K. Buzzard, O. Skibina, M. Terzi, M. Slee, C. Solaro, . Oreja-Guevara, C. Ramo-Tello, Y. Fragoso, V. Shaygannejad, F. Moore, C. Rajda, E. Aguera Morales, H. Butzkueven
- 520 9_
- $a AIM: To evaluate the real-world comparative effectiveness and the cost-effectiveness, from a UK National Health Service perspective, of natalizumab versus fingolimod in patients with rapidly evolving severe relapsing-remitting multiple sclerosis (RES-RRMS). METHODS: Real-world data from the MSBase Registry were obtained for patients with RES-RRMS who were previously either naive to disease-modifying therapies or had been treated with interferon-based therapies, glatiramer acetate, dimethyl fumarate, or teriflunomide (collectively known as BRACETD). Matched cohorts were selected by 3-way multinomial propensity score matching, and the annualized relapse rate (ARR) and 6-month-confirmed disability worsening (CDW6M) and improvement (CDI6M) were compared between treatment groups. Comparative effectiveness results were used in a cost-effectiveness model comparing natalizumab and fingolimod, using an established Markov structure over a lifetime horizon with health states based on the Expanded Disability Status Scale. Additional model data sources included the UK MS Survey 2015, published literature, and publicly available sources. RESULTS: In the comparative effectiveness analysis, we found a significantly lower ARR for patients starting natalizumab compared with fingolimod (rate ratio [RR] = 0.65; 95% confidence interval [CI], 0.57-0.73) or BRACETD (RR = 0.46; 95% CI, 0.42-0.53). Similarly, CDI6M was higher for patients starting natalizumab compared with fingolimod (hazard ratio [HR] = 1.25; 95% CI, 1.01-1.55) and BRACETD (HR = 1.46; 95% CI, 1.16-1.85). In patients starting fingolimod, we found a lower ARR (RR = 0.72; 95% CI, 0.65-0.80) compared with starting BRACETD, but no difference in CDI6M (HR = 1.17; 95% CI, 0.91-1.50). Differences in CDW6M were not found between the treatment groups. In the base-case cost-effectiveness analysis, natalizumab dominated fingolimod (0.302 higher quality-adjusted life-years [QALYs] and £17,141 lower predicted lifetime costs). Similar cost-effectiveness results were observed across sensitivity analyses. CONCLUSIONS: This MSBase Registry analysis suggests that natalizumab improves clinical outcomes when compared with fingolimod, which translates to higher QALYs and lower costs in UK patients with RES-RRMS.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a natalizumab $x terapeutické užití $7 D000069442
- 650 _2
- $a fingolimod hydrochlorid $x terapeutické užití $7 D000068876
- 650 12
- $a relabující-remitující roztroušená skleróza $x farmakoterapie $7 D020529
- 650 _2
- $a imunosupresiva $x terapeutické užití $7 D007166
- 650 12
- $a roztroušená skleróza $x farmakoterapie $7 D009103
- 650 _2
- $a analýza nákladové efektivity $7 D000094703
- 650 _2
- $a analýza nákladů a výnosů $7 D003362
- 650 _2
- $a státní lékařství $7 D013222
- 651 _2
- $a Spojené království $7 D006113
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Herring, W L $u Health Economics, RTI Health Solutions, NC, USA $u Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden $1 https://orcid.org/0000000182229914
- 700 1_
- $a Acosta, C $u Value and Access, Biogen, Baar, Switzerland $1 https://orcid.org/0000000272578675
- 700 1_
- $a Hyde, R $u Medical, Biogen, Baar, Switzerland
- 700 1_
- $a Jokubaitis, V G $u Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia $1 https://orcid.org/0000000239424340
- 700 1_
- $a Pucci, E $u Neurology Unit, AST-Fermo, Fermo, Italy
- 700 1_
- $a Lugaresi, A $u Dipartamento di Scienze Biomediche e Neuromotorie, Università di Bologna, Bologna, Italy $u IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy
- 700 1_
- $a Laureys, G $u Department of Neurology, University Hospital Ghent, Ghent, Belgium
- 700 1_
- $a Havrdova, E K $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Horakova, D $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Izquierdo, G $u Department of Neurology, Hospital Universitario Virgen Macarena, Seville, Spain
- 700 1_
- $a Eichau, S $u Department of Neurology, Hospital Universitario Virgen Macarena, Seville, Spain
- 700 1_
- $a Ozakbas, S $u Izmir University of Economics, Medical Point Hospital, Izmir, Turkey
- 700 1_
- $a Alroughani, R $u Division of Neurology, Department of Medicine, Amiri Hospital, Sharq, Kuwait
- 700 1_
- $a Kalincik, T $u Neuroimmunology Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia $u CORe, Department of Medicine, University of Melbourne, Melbourne, Australia
- 700 1_
- $a Duquette, P $u CHUM and Universite de Montreal, Montreal, Canada
- 700 1_
- $a Girard, M $u CHUM and Universite de Montreal, Montreal, Canada
- 700 1_
- $a Petersen, T $u Aarhus University Hospital, Arhus C, Denmark
- 700 1_
- $a Patti, F $u Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania, Italy $u UOS Sclerosi Multipla, AOU Policlinico "G Rodloico-San Marco", University of Catania, Italy $1 https://orcid.org/0000000269230846
- 700 1_
- $a Csepany, T $u Department of Neurology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary $1 https://orcid.org/0000000283053209
- 700 1_
- $a Granella, F $u Department of Medicine and Surgery, University of Parma, Parma, Italy $u Department of General Medicine, Parma University Hospital, Parma, Italy
- 700 1_
- $a Grand'Maison, F $u Neuro Rive-Sud, Quebec, Canada
- 700 1_
- $a Ferraro, D $u Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, Italy
- 700 1_
- $a Karabudak, R $u Hacettepe University, Ankara, Turkey
- 700 1_
- $a Jose Sa, M $u Department of Neurology, Centro Hospitalar Universitario de Sao Joao, Porto, Portugal $u Faculty of Health Sciences, University Fernando Pessoa, Porto, Portugal
- 700 1_
- $a Trojano, M $u School of Medicine, University of Bari, Bari, Italy
- 700 1_
- $a van Pesch, V $u Cliniques Universitaires Saint-Luc, Brussels, Belgium $u Université Catholique de Louvain, Belgium
- 700 1_
- $a Van Wijmeersch, B $u University MS Centre, Hasselt-Pelt and Noorderhart Rehabilitation & MS, Pelt and Hasselt University, Hasselt, Belgium
- 700 1_
- $a Cartechini, E $u Neurology unit, AST Macerata, Macerata, Italy
- 700 1_
- $a McCombe, P $u University of Queensland, Brisbane, Australia $u Royal Brisbane and Women's Hospital, Herston, Australia
- 700 1_
- $a Gerlach, O $u Academic MS Center Zuyd, Department of Neurology, Zuyderland Medical Center, Sittard-Geleen, The Netherlands $u School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands
- 700 1_
- $a Spitaleri, D $u Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino, Avellino, Italy
- 700 1_
- $a Rozsa, C $u Jahn Ferenc Teaching Hospital, Budapest, Hungary
- 700 1_
- $a Hodgkinson, S $u Immune Tolerance Laboratory Ingham Institute and Department of Medicine, UNSW, Sydney, Australia
- 700 1_
- $a Bergamaschi, R $u IRCCS Mondino Foundation, Pavia, Italy
- 700 1_
- $a Gouider, R $u Department of Neurology, LR18SP03 and Clinical Investigation Center Neurosciences and Mental Health, Razi University Hospital -, Mannouba, Tunis, Tunisia $u Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia
- 700 1_
- $a Soysal, A $u Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases, Istanbul, Turkey
- 700 1_
- $a Castillo-Triviño, $u Hospital Universitario Donostia and IIS Biodonostia, San Sebastián, Spain
- 700 1_
- $a Prevost, J $u CSSS Saint-Jérôme, Saint-Jerome, Canada
- 700 1_
- $a Garber, J $u Westmead Hospital, Sydney, Australia
- 700 1_
- $a de Gans, K $u Groene Hart Ziekenhuis, Gouda, Netherlands
- 700 1_
- $a Ampapa, R $u Nemocnice Jihlava, Jihlava, Czech Republic
- 700 1_
- $a Simo, M $u Department of Neurology, Semmelweis University Budapest, Budapest, Hungary
- 700 1_
- $a Sanchez-Menoyo, J L $u Department of Neurology, Galdakao-Usansolo University Hospital, Osakidetza Basque Health Service, Galdakao, Spain $u Biocruces-Bizkaia Health Research Institute, Spain
- 700 1_
- $a Iuliano, G $u Ospedali Riuniti di Salerno, Salerno, Italy
- 700 1_
- $a Sas, A $u Department of Neurology and Stroke, BAZ County Hospital, Miskolc, Hungary
- 700 1_
- $a van der Walt, A $u Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia $u Department of Neurology, The Alfred Hospital, Melbourne, Australia
- 700 1_
- $a John, N $u Monash University, Clayton, Australia $u Department of Neurology, Monash Health, Clayton, Australia
- 700 1_
- $a Gray, O $u South Eastern HSC Trust, Belfast, United Kingdom
- 700 1_
- $a Hughes, S $u Royal Victoria Hospital, Belfast, United Kingdom
- 700 1_
- $a De Luca, G $u MS Centre, Neurology Unit, "SS. Annunziata" University Hospital, University "G. d'Annunzio", Chieti, Italy
- 700 1_
- $a Onofrj, M $u Department of Neuroscience, Imaging, and Clinical Sciences, University G. d'Annunzio, Chieti, Italy
- 700 1_
- $a Buzzard, K $u Department of Neurosciences, Box Hill Hospital, Melbourne, Australia $u Monash University, Melbourne, Australia $u MS Centre, Royal Melbourne Hospital, Melbourne, Australia
- 700 1_
- $a Skibina, O $u Department of Neurology, The Alfred Hospital, Melbourne, Australia $u Monash University, Melbourne, Australia $u Department of Neurology, Box Hill Hospital, Melbourne, Australia
- 700 1_
- $a Terzi, M $u Medical Faculty, 19 Mayis University, Samsun, Turkey
- 700 1_
- $a Slee, M $u Flinders University, Adelaide, Australia
- 700 1_
- $a Solaro, C $u Department of Neurology, ASL3 Genovese, Genova, Italy $u Department of Rehabilitation, ML Novarese Hospital Moncrivello
- 700 1_
- $a Oreja-Guevara, $u Department of Neurology, Hospital Clinico San Carlos, Madrid, Spain
- 700 1_
- $a Ramo-Tello, C $u Department of Neuroscience, Hospital Germans Trias i Pujol, Badalona, Spain
- 700 1_
- $a Fragoso, Y $u Universidade Metropolitana de Santos, Santos, Brazil
- 700 1_
- $a Shaygannejad, V $u Isfahan University of Medical Sciences, Isfahan, Iran
- 700 1_
- $a Moore, F $u Department of Neurology, McGill University, Montreal, Canada
- 700 1_
- $a Rajda, C $u Department of Neurology, University of Szeged, Szeged, Hungary
- 700 1_
- $a Aguera Morales, E $u Department of Medicine and Surgery, University of Cordoba, Cordoba, Spain $u Maimonides Biomedical Research Institute of Cordoba (IMIBIC)
- 700 1_
- $a Butzkueven, H $u Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia
- 773 0_
- $w MED00193522 $t Journal of medical economics $x 1941-837X $g Roč. 27, č. 1 (2024), s. 109-125
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38085684 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240213092946 $b ABA008
- 999 __
- $a ok $b bmc $g 2049034 $s 1209795
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 27 $c 1 $d 109-125 $e 20231226 $i 1941-837X $m Journal of medical economics $n J Med Econ $x MED00193522
- LZP __
- $a Pubmed-20240109
